Liraglutide and dulaglutide, as GLP-1R agonists, can improve AD-related cognitive dysfunction by inhibiting tau protein hyperphosphorylation and NFTs formation through activation of the protein kinase B/glycogen synthase kinase 3 beta (Akt/GSK-3β) signaling pathway (Shu et al., 2019; Zhou et al., 2019). Here, AKT1 is linked to Alzheimer disease.